Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 33
mi
from
Detroit, MI
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 33
mi
from
Detroit, MI
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 20
mi
from
Fridley, MN
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 20
mi
from
Fridley, MN
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 22
mi
from
New York, NY
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 22
mi
from
New York, NY
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 14
mi
from
High Point, NC
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 14
mi
from
High Point, NC
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 39
mi
from
Bexley, OH
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 39
mi
from
Bexley, OH
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 15
mi
from
Pittsburgh, PA
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 15
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 19
mi
from
College Station, TX
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 19
mi
from
College Station, TX
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 37
mi
from
Houston, TX
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 37
mi
from
Houston, TX
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 23
mi
from
San Antonio, TX
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 23
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 24
mi
from
Webster, TX
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 24
mi
from
Webster, TX
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 31
mi
from
Norfolk, VA
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 31
mi
from
Norfolk, VA
Click here to add this to my saved trials
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated:  12/31/1969
Arcutis Clinical Site 18
mi
from
Surrey,
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis
Status: Enrolling
Updated: 12/31/1969
Arcutis Clinical Site 18
mi
from
Surrey,
Click here to add this to my saved trials
Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis
An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis
An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fountain Valley, CA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
La Mesa, CA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
La Mesa, CA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Upland, CA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Upland, CA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Boulder, CO
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Boulder, CO
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Danbury, CT
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Danbury, CT
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tamarac, FL
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tamarac, FL
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Coeur d'Alene, ID
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Bowling Green, KY
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Bowling Green, KY
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Lincoln, NE
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Omaha, NE
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Durham, NC
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
New Bern, NC
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
New Bern, NC
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Bethlehem, PA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Arlington, TX
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mesquite, TX
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mesquite, TX
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Burlington, VT
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Burlington, VT
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Kennewick, WA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Kennewick, WA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Seattle, WA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Spokane, WA
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Glendale, WI
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Glendale, WI
Click here to add this to my saved trials
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Kogarah,
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Kogarah,
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Monroe, LA
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Monroe, LA
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lebanon, NH
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Salisbury, NC
A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis.
A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Salisbury, NC
Click here to add this to my saved trials